secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-03-20T23:59:59+00:00
Accession:  0001213900-24-024305
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed granted 180-day Nasdaq extension to regain minimum bid compliance
-----------------------------------------------------------------------

- Nasdaq extended compliance period to Sept 16, 2024 to meet $1.00 minimum bid price.
- Must achieve closing bid of $1.00 or more for 10 consecutive business days.
- Previously notified of non-compliance on Sept 19, 2023; original deadline was March 18, 2024.
- Company may consider a reverse stock split if needed; no immediate effect on trading.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024024305/0001213900-24-024305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024024305/ea0202208-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-024305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer